Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ecotropic viral integration site 2B protein homolog (EVI2B)
- Target
- EVI2B
- Molecular classification
- Other (transmembrane glycoprotein, not classified as a canonical receptor, enzyme, transporter, or ion channel)
01
Overview
Ecotropic viral integration site 2B protein homolog (EVI2B, also known as CD361) is a transmembrane glycoprotein encoded within an intron of the NF1 gene. It is predominantly localized to the plasma membrane and is expressed widely in hematopoietic cells, with highest levels in mature granulocytes. EVI2B is required for granulocyte differentiation and proper function of hematopoietic progenitor cells, influencing their cell cycle progression and survival. It acts as a direct downstream target of the transcription factor C/EBPα. Loss or knockdown of EVI2B impairs myeloid lineage development and hematopoietic stem/progenitor cell functionality. Expression of EVI2B can be dysregulated in acute myeloid leukemia, especially in cases with CEBPA mutations, and may also play a role in modifying the phenotype of neurofibromatosis type 1 and its associated risk of malignancies. The precise molecular function remains under investigation, and EVI2B is not currently targeted by approved therapeutics or drugs
- Other names
- EVI2BEVDBCD361EVI-2BD17S376Ecotropic viral integration site 2B protein homologprotein EVI2B
02
Biological functions
Positive regulation of granulocyte differentiationRegulation of hematopoietic progenitor cell survival and cell cycle progressionRegulation of myeloid lineage and hematopoiesis
03
Disease associations
Cancer (particularly acute myeloid leukemia and possibly other hematological malignancies)Neurofibromatosis type 1 and associated tumorigenesis
04
Biomarkers
Downregulation in AML with CEBPA defects may help stratify certain leukemiasExpression status may be explored as a modifier in neurofibromatosis type 1
Beyond the preview
Go deeper on Ecotropic viral integration site 2B protein homolog (EVI2B).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ecotropic viral integration site 2B protein homolog (EVI2B).